SCHEMBL4421726

SCHEMBL4421726

CCOC(=O)COc1ccc(NC(=O)OC(C)(C)C)c2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.47
CASP7 P55210 1/20 0.47
CASP9 P55211 1/20 0.47
NLRP3 Q96P20 4/20 0.46
ALDH1A1 P00352 2/20 0.45
HPGD P15428 2/20 0.45
AAK1 Q2M2I8 2/20 0.44
KDM4E B2RXH2 4/20 0.43
CDC25B P30305 1/20 0.42
MAPK1 P28482 2/20 0.42
MITF O75030 1/20 0.42
LMNA P02545 1/20 0.42
HSP90AA1 P07900 1/20 0.42
MAPT P10636 1/20 0.42
PKM P14618 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
TLR9 Q9NR96 1/20 0.42
USP2 O75604 1/20 0.42
CYP2D6 P10635 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4416482 0.85 CASP3 (0.46) CASP3CASP7CASP9ALDH1A1HPGD
SCHEMBL4421619 0.81 CASP3 (0.54) CASP3CASP7CASP9NLRP3ALDH1A1
SCHEMBL4689617 0.80 AAK1 (0.44) ALDH1A1HPGDAAK1CDC25BLMNA
SCHEMBL593474 0.80 AAK1 (0.47) AAK1CDC25BMAPTCYP2D6
SCHEMBL593957 0.80 AAK1 (0.47) AAK1CDC25BMAPTCYP2D6
SCHEMBL6279532 0.80 BRD4 (0.48) AAK1CYP2D6NPC1
SCHEMBL592972 0.80 AAK1 (0.47) AAK1CDC25BMAPTCYP2D6
SCHEMBL7501276 0.80 AAK1 (0.47) AAK1CDC25BLMNAMAPTCYP2D6
SCHEMBL18593710 0.77 AAK1 (0.43) ALDH1A1HPGDAAK1CDC25BLMNA
SCHEMBL4855183 0.77 ESR1 (0.51) NLRP3ALDH1A1AAK1MAPK1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495001-B2 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
EP-1682507-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2006-07-26 EP disclosed
WO-2005049572-A1 BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2005-06-02 WO disclosed
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2005-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050096336-A1 Benzannelated derivatives, their manufacture and use as pharmaceutical agents PPARD, PPARA, PPARG CASP3 718/4885CASP7 1348/4885CASP9 1022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.